Complement Therapeutics GmbH (CTx), a UK-based preclinical stage biotechnology company, announced on Thursday that it has named Dr Parisa Zamiri as its new chief medical officer, effective immediately.

Dr Zamiri has extensive experience in biopharmaceutical and small molecule drug discovery and development, drug and device safety, pharmacovigilance, and biomarker development across various therapeutic areas. She has served as chief medical officer at Graybug Vision, Inc and vice president, global head of Clinical Development and therapeutic area head for Ophthalmology at Novartis Pharmaceuticals.

Dr Rafiq Hasan, Complement Therapeutics chief executive officer, said, 'We are excited to welcome Parisa to the CTx team as CMO. Parisa's clinical experience and deep expertise in ophthalmic clinical development will be crucial as we progress with the development of our novel pipeline assets, particularly CTx001 for the treatment of Geographic Atrophy secondary to AMD as well as the ongoing i-GAIN natural history study. We are thrilled to have her on board to support our vision of developing the next generation of complement medicines.'